Project Grant R44AI131749

The Defense Health Agency awarded a $215,429 Project Grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis. This two-year grant, running from July 2024 to July 2026, supports TB Alliance's research and development efforts to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The funding falls under the Military...

This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...

This $7,352,643 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports efforts by The Global Alliance For TB Drug Development Inc. (TB Alliance) to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The grant, awarded on September 30, 2024 with a completion date of September 29, 2028, will fund TB Alliance's research on innovative, host-directed approaches to target...

The National Science Foundation awarded PZA Innovation LLC a $270,509 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop reliable pyrazinamide susceptibility testing at neutral pH. The grant period runs from January 1, 2022 through October 31, 2023. Under this award, PZA Innovation LLC will deliver products and services focused on advancing science and engineering research and innovation leading to breakthrough technologies for national and...

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

Federal Grant Award Summary Fimbrion Therapeutics Inc. received a $300,000 Project Grant award dated September 9, 2025, from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855). The two-year project, with completion targeted for August 31, 2027, supports the preclinical development and advancement of thiazolino-pyridone (TZP) small molecule compounds as novel antimycobacterial agents to treat tuberculosis (TB). The...

Federal Project Grant Award Summary Tarn Biosciences, Inc. received a $298,829 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 21, 2025. The grant supports the development of nitroreductase-activated inhibitor compounds, specifically advancing the parent compound HC2210, for the treatment of both drug-susceptible and drug-resistant tuberculosis (TB) and non-tuberculous...

Federal Grant Award Summary Taxis Pharmaceuticals Inc. received a $1.0M Small Business Innovation Research (SBIR) Phase 2 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 16, 2025, with a completion date of April 30, 2028. The award supports lead optimization and development of an oral dihydrofolate reductase (DHFR) inhibitor therapeutic to treat multidrug-resistant Neisseria...

Federal Project Grant Award Summary Progenra Inc. received a $302,421 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 16, 2025, with a completion date of April 30, 2027. This Phase I Small Business Innovation Research (SBIR) grant supports the development of small molecule parkin activators as novel antituberculosis therapeutics. The project leverages Progenra's proprietary...

Federal Project Grant Award Summary Fimbrion Therapeutics Inc. received a $300,001 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2027. The award supports the development of heterocyclic small molecule inhibitors targeting QcrB, a respiratory protein in nontuberculous mycobacteria (NTM), specifically to address...